PVLA — Palvella Therapeutics, Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Palvella Therapeutics, Inc

Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformation… Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$113.99
Market Cap$1.66B
Float9.6M
Shares Outstanding14.3M
vs. Analyst Target+100.9% to analyst PT
Dividend RateNone
Analyst Target Price$229.00 (9 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $29.3M -$37.2M $29.3M -$34.9M
2021 $31.4M -$45.7M $29.1M -$43.4M
2022 $25.9M -$33.3M $23.1M -$30.5M
2023 N/A $18.7M N/A $18.7M
2024 N/A -$17.4M N/A -$13.1M
2025 N/A -$41.7M N/A -$35.9M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$9.5M
Sep 2025 N/A -$11.3M
Dec 2025 N/A -$12.7M
Mar 2026 N/A -$15.8M

Ownership & Float

Insider Ownership11.6%
Institutional Ownership95.9%
Short Float22.7%
% of All Funds Holding2.00%
Number of Funds Holding164

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$120.54Near-term / short-term trend
Weekly40-Week SMA$94.02Medium-term trend
Weekly80-Week SMA$58.28Cyclical trend (business cycle)
Weekly200-Week SMA$51.36Secular trend (multi-year)
Monthly10-Month SMA$98.28Near-term monthly trend
Monthly20-Month SMA$59.81Medium-term monthly trend
Monthly40-Month SMA$44.51Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$80.00 support 1.96x 2 months ago
$64.00 support 1.71x 6 months ago
$36.70 support 1.55x 8 months ago
$22.60 support 2.46x 9 months ago
$19.10 support 1.36x 13 months ago

Historical Earnings Reactions (45 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.46% 0.26% 53.33% 17.39% -5.21%
1 Day 2.35% 2.40% 66.67% 34.16% -15.72%
1 Week 3.05% 2.41% 57.78% 95.83% -26.72%
2 Weeks 4.20% 0.55% 51.11% 65.63% -32.26%
1 Month 2.53% -3.92% 44.44% 83.85% -43.32%

Next earnings: July 26, 2026 (60 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan6.9%63.6%11
Feb9.5%58.3%12
Mar0.3%41.7%12
Apr-7.1%25.0%12
May15.6%54.5%11
Jun-9.1%36.4%11
Jul16.9%72.7%11
Aug11.8%63.6%11
Sep-9.0%36.4%11
Oct-5.0%27.3%11
Nov6.7%54.5%11
Dec-5.1%36.4%11

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.09% 47.9% 535
Tuesday 0.33% 42.4% 589
Wednesday 0.13% 46.6% 586
Thursday -0.22% 41.0% 576
Friday 0.30% 49.0% 573

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 95.9%

Insider Transactions — Smart Summary

Total insider ownership: 11.6%

Founder-led management: Wes Kaupinen (Founder, President, CEO & Director)

12-Month Insider Activity Summary

Total Filings10
Net Value-$2.8M
Net Shares Change6,845
% of Float0.1%
C-Suite Filings7
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
Goin Kathleen Chief Operating Officer -$2.8M 7 N/A
JENKINS GEORGE M +$549,973.5 2 2 buy
HERON ELAINE J +$300,000 1 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-02-20 – 2026-03-02 3 3 +$493,319.024 1 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-02 JENKINS GEORGE M +$500,000 Transaction at $125.00, now -8.8%
2026-03-02 HERON ELAINE J +$300,000 Transaction at $125.00, now -8.8%
2026-04-01 JENKINS GEORGE M +$49,973.5 Transaction at $112.30, now +1.5%
2026-05-22 Goin Kathleen Chief Operating Officer -$440,747.644 Transaction at $59.33, now +92.1%
2026-04-17 Goin Kathleen Chief Operating Officer -$512,515.759 Transaction at $67.68, now +68.4%
2026-03-20 Goin Kathleen Chief Operating Officer -$472,727.851 Transaction at $63.05, now +80.8%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Palvella Therapeutics, Inc (PVLA) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for PVLA on Trend Edge →